AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Using Systemic Treatments for Atopic Dermatitis Safely - Monitoring and Recognizing Adverse Events

Description

The presentation covers the safe use of systemic treatments for atopic dermatitis (AD), focusing on monitoring patients and identifying potential adverse events. It emphasizes the importance of clinical judgment in determining the frequency of patient monitoring based on their medication and comorbidities, as guidelines offer limited specific instructions. Key concerns include identifying serious skin reactions like Erythema Multiforme, which can occur with immunosuppressants. It is crucial to monitor for staph aureus colonization in AD patients, as it is commonly misinterpreted as an infection. The use of systemic steroids is cautioned against due to their tendency to lead to disease rebound and complications like osteoporosis. Traditional immunosuppressants such as cyclosporine are effective, but require careful monitoring of renal function and blood pressure. The benefits of biologics and jacks, including their lower monitoring requirements, were discussed, although patients should be warned about specific risks like conjunctivitis and facial dermatitis. The presentation also highlights the importance of considering vaccination in patients on systemic treatments, as live vaccines may not be recommended. Overall, the session stresses the significance of personalized care in managing AD while maintaining a vigilance for adverse events.

View more

Conclusions

  • Monitoring for adverse events is crucial for patients on biologic and systemic therapies for atopic dermatitis.
  • Clinical judgment plays a major role in treatment and monitoring decisions due to variability in provider practices.
  • Eczema herpeticum is a significant concern, particularly in patients on immunosuppressive therapies, with a high recurrence rate.
  • Dupilumab and other targeted therapies can lower Staphylococcus aureus colonization in patients with atopic dermatitis.
  • Systemic corticosteroids should be used sparingly, as their use may lead to rebound flares and increased risk of osteoporosis and fractures.
  • Switching between biologics or to JAK inhibitors may provide relief for patients experiencing adverse events from previous treatments.
  • Patient-specific factors, including comorbidities and medication history, should guide monitoring frequency and laboratory assessments.
  • JAK inhibitors present reassuring safety profiles when monitored in clinical practice.
  • Facial dermatitis and conjunctivitis are common adverse effects that require proactive management and monitoring during treatment.
  • Overall, individualized treatment strategies should be adopted to ensure effective management of atopic dermatitis while minimizing risks.
  • Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024 Feb;90(2):e43-e56. doi: 10.1016/j.jaad.2023.08.102. Epub 2023 Nov 7. PMID: 37943240.
  • AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel; Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, et al .: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024 Mar;132(3):274-312. doi: 10.1016/j.anai.2023.11.009. Epub 2023 Dec 18. PMID: 38108679.
  • Traidl S, et al. TREATgermany Study Group. High recurrence rate of eczema herpeticum in moderate/severe atopic dermatitis -TREATgermany registry analysis. J Dtsch Dermatol Ges. 2023 Dec;21(12):1490-1498. Epub 2023 Oct 9. PMID: 37814394.
  • Gao L, et al. Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum. J Allergy Clin Immunol. 2015 Dec;136(6):1591-1600. doi: 10.1016/j.jaci.2015.06.047.
  • Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024 Feb;90(2):e43-e56. doi: 10.1016/j.jaad.2023.08.102. Epub 2023 Nov 7. PMID: 37943240.
  • Haganström K, Klinger T, Müller K, Willers C, Augustin M. Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis. Br J Dermatol. 2024 Oct 17;191(5):719-727. doi: 10.1093/bjd/ljae250. PMID: 38924726.
  • Wu D, Wu XD, Zhou X, Huang W, Luo C, Liu Y. Bone mineral density, osteopenia, osteoporosis, and fracture risk in patients with atopic dermatitis: a systematic review and meta-analysis. Ann Transl Med. 2021 Jan;9(1):40. PMC7859773.
  • Schmitt J, Schäkel K, Fölster-Holst R, Bauer A, Oertel R, Augustin M, Aberer W, Luger T, Meurer M. Prednisolone vs. ciclosporin for severe adult eczema: An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol. 2010 Mar;162(3):661-668.
  • Sidbury R, et al. American Academy of Dermatology. Guidelines of Care for the Management of Atopic Dermatitis: Section 3. Management and Treatment with Phototherapy and Systemic Agents. J Am Acad Dermatol. 2014 Aug;71(2):327-49. DOI: 10.1016/j.jaad.2014.03.047.
  • Hasan I, Parsons L, Duran S, Zinn Z. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. J Am Acad Dermatol. 2024 Aug;91(2):255-258. doi: 10.1016/j.jaad.2024.03.039. Epub 2024 Apr 6. PMID: 38588818.